Shots:
- UK’s MHRA has approved Tepezza (teprotumumab) for the treatment of adult pts with mod. to sev. thyroid eye disease (TED)
- Approval was based on extensive clinical data incl. P-III (OPTIC) trial (n=83), P-II (TED01RV) trial (n=88), P-IV (HZNP-TEP-403) trial (n=62) & P-III (OPTIC-J) trial in Japan (n=54)
- OPTIC trial showed that 83% (34/41) of teprotumumab-treated pts had ≥2mm proptosis reduction compared to 10% (4/42) on PBO at 24wks.
Ref: Businesswire | Image: Amgen
Related News:- Amgen Reports P-III (DeLLphi-304) Trial Findings of Imdelltra for SCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
